Table 4.

Longitudinal analysis of association between lupus biomarkers and SLE disease activity, using SLAM and modified SELENA–SLEDAI scores in 156 SLE patients^*

	Partial R2†	Coefficient	SE	P
SLAM
Regression model 1
C3	0.007	−1.09	0.48	0.025
C4	0.001	0.27	0.29	0.36
Anti-dsDNA	0.030	1.17	0.26	<0.0001
E-C3d	0.011	0.08	0.03	0.005
Regression model 2
C3	0.007	−1.09	0.48	0.023
C4	0.001	0.27	0.29	0.35
Anti-dsDNA	0.029	1.16	0.26	<0.0001
E-C4d	0.011	0.02	0.008	0.006
Modified SELENA-SLEDAI‡
Regression model 3
C3	0.013	−1.05	0.36	0.003
C4	0.004	0.33	0.21	0.11
Anti-dsDNA	0.014	0.61	0.19	0.002
E-C3d	0.004	0.032	0.02	0.11
Regression model 4
C3	0.012	−1.03	0.36	0.004
C4	0.004	0.35	0.21	0.099
Anti-dsDNA	0.014	0.60	0.19	0.002
E-C4d	0.007	0.01	0.01	0.03

^*SLE = systemic lupus erythematosus; SLAM = Systemic Lupus Activity Measure; E-C3d = erythrocyte-bound C3d.

^†Type II sums of squares test.

^‡The modified Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index (SELENA–SLEDAI) excluded serum C3, C4, and anti–double-stranded DNA (anti-dsDNA) parameters.